Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico

Table 3

Mortality-related quantitative characteristics of the population.

Characteristic	Alive	Death	value
Onset of the symptoms	8.25 ± 3.884	9 ± 4.493	0.47
Age	47.6 ± 11.32	54.45 ± 12.32	0.025
BMI	29.1 ± 4.91	29.43 ± 5.34	0.824
SaO2% without O2	74.33 ± 13.98	71.55 ± 10.34	0.40
SaO2% with O2	87.75 ± 9.39	85.64 ± 5.84	0.331
Heart rate	91.35 ± 16.04	94.36 ± 18.16	0.487
Respiratory rate	23.54 ± 4.32	24.73 ± 5.17	0.321
Leucocytes	9.35 ± 4.97	12.37 ± 3.27	0.012
Neutrophils	8.05 ± 4.91	11.13 ± 3.20	0.009
Lymphocytes	0.93 ± 0.52	0.70 ± 0.42	0.075
Glucose	137.43 ± 73.57	184.40 ± 144.84	0.163
ALT	66.01 ± 95.00	43.04 ± 38.63	0.327
AST	73.73 ± 148.66	51.39 ± 58.29	0.529
LDH	487.88 ± 327.41	505.31 ± 182.31	0.844
Total bilirubin	0.61 ± 0.38	0.69 ± 0.27	0.474
CK	105.65 ± 111.02	122.15 ± 84.85	0.706
Glomerular filtration rate	94.80 ± 25.50	75.10 ± 35.79	0.030
Fibrinogen	1513 ± 2803.29	862.80 ± 453.92	0.617
PCR	18.04 ± 10.23	26.68 ± 13.16	0.012